Target Engagement Biomarker Tools for Parkinson's Disease Therapeutics. High-Purity Phospho-Specific Reagents for LRRK2 Kinase Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LRRK2 pS935 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LRRK2 Recombinant Protein (WT, S935A, S935D Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View LRRK2 Products |
| Gene Delivery | LRRK2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Native phosphorylation capability. |
View LRRK2 Products |
| Benchmark Ab | Anti-LRRK2 (Phospho S935) Rabbit mAb Recombinant phospho-specific clone. Sequence Verified. For PD biomarker detection. |
View LRRK2 Products |
| Validator | LRRK2 siRNA Set For knockdown verification and assay specificity confirmation. |
View LRRK2 Products |
| Related Target LRRK1 | LRRK1 Protein Close homolog for kinase selectivity screening (avoid off-target inhibition). |
View LRRK1 Products |
| Related Target RAB10 | RAB10 Protein Downstream substrate/effector for pathway validation assays. |
View RAB10 Products |
| Related Target G2019S | LRRK2 G2019S Recombinant Protein Major Parkinson's disease-associated mutant kinase for selective inhibitor profiling. |
View LRRK2 G2019S Products |
| Related Target 14-3-3 | 14-3-3 Protein (Pan isoform) Interacting partner regulated by pS935, supporting mechanism-of-action studies. |
View 14-3-3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Phospho-Specific Detection (Distinguish pS935 vs Total LRRK2) | Anti-LRRK2 pS935 Recombinant mAb with S935A Negative Control Protein Pair |
| Mutant Control Standardization | Purified S935A (Non-phosphorylatable) and S935D (Phospho-mimetic) Proteins for Assay Calibration |
| Selectivity vs Close Homolog LRRK1 | Human LRRK1 Recombinant Protein Available for Cross-reactivity Panels |
| Cellular Target Engagement Validation | Lentivirus Premade Particles for Stable LRRK2-Overexpressing Cell Lines (Compatible with pS935 detection) |
| False Positives in Biomarker Assays | Sequence-Verified siRNA for Target Specificity Confirmation |
| Kinase Inhibitor Screening | High-purity recombinant LRRK2 proteins (WT and mutants) strictly verified by mass spec |
Live LRRK2 pS935 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active LRRK2 Clinical Trials
- Latest pS935 Biomarker Research
- Resistance & Mutation Analysis
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The LRRK2 inhibitor landscape is maturing rapidly, with first-generation small molecules entering Phase II trials for Parkinson's Disease. The phosphorylation status at Serine 935 (pS935) has emerged as the critical pharmacodynamic biomarker, reliably indicating target engagement in peripheral blood and potentially in CSF. Major players like Denali Therapeutics (partnered with Biogen) advance DNL151 and DNL343, while Novartis explores backup series, and Ionis/Biogen pursue ASO approaches. The industry is shifting toward CNS-penetrant inhibitors with quantifiable pS935 modulation. Future development focuses on combining LRRK2 inhibition with immunomodulatory agents, PROTAC-mediated degradation, and establishing pS935 as a surrogate endpoint for disease modification.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Denali/Biogen, Novartis, AbbVie | Parkinson's Disease (G2019S carriers & idiopathic) | pS935 Biomarker Assay (Need phospho-specific Ab + mutant controls) |
| PROTACs | Emerging Academic/Startup | Neurodegeneration | Cellular Phospho-Degradation Assay (Need Lentivirus + siRNA) |
| Biomarker Diagnostics | BioLegend, Abcam, TarMart | PD Progression Monitoring | Quantitative pS935 Standard (Need calibrated S935D protein) |
| ASO / siRNA | Ionis, Biogen | Neurodegeneration | Knockdown Validation (Need exact target quantification) |